Macomics expands in Edinburgh, appoints Professor Paul Crocker to SAB

Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB).

Macomics’ operations are located in Edinburgh and Cambridge, two major hubs of life science research in the UK with R&D teams split 50:50 across both sites. To accommodate expansion and to be co-located in an entrepreneurial centre of scientific excellence, Macomics has recently moved to dedicated laboratories in the Roslin Innovation Centre. The new facilities are 50% larger than its founding base at Edinburgh University.

“The Roslin Innovation Centre Easter Bush Campus provides a dynamic and vibrant working environment with world-class facilities equipped with the latest technologies” Stephen Myatt, CEO of Macomics.

Macomics, the brainchild of world-recognised experts in macrophage biology, the late Prof Jefferey Pollard and Macomics VP immunology and co-founder, Dr Luca Cassetta, is exploiting the potential of macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Whilst it is the only human drug discovery company at the incubator, other companies exploiting macrophage biology for animal health provide for a productive scientific exchange.

Macomics’ ENIGMAC macrophage drug discovery platform integrates large volume human data sets, custom cell models, and proprietary human macrophage genome editing capability to discover novel targets and unlock disease specific target biology. Macrophages (TAMs) are often the most abundant immune cell many types of cancer and modulating TAMs can enhance the body’s ability to fight cancer.

Maximising on local expertise and connections, Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee has joined Macomics’ SAB. Prof. Crocker is a recognised expert in the understanding how immune cells utilise host glycans to regulate immune and inflammatory responses and translating this to human disease. 

Dr Luca Cassetta, VP immunology and co-founder of Macomics said, “It is a pleasure to welcome Paul to our SAB, having been local academic colleagues over many years. Our SAB is very International but having Paul’s expertise on our doorstep in Scotland and his knowledge of glycoimmunology and immune and inflammatory responses adds important expertise as we advance our macrophage targeting drug discovery programmes.”


More news and updates 

Hartmut van Lengerich appointed as Chairman of Moa Technology

With over 30 years’ experience in global strategic and operational roles, including serving as Bayer Crop Science’s CEO for Canada, Global Head of Cereals, Head of Fungicides and, most recently, SVP Global Crop Protection Asset Management at Bayer AG, overseeing $13bn in worldwide sales

ACROBiosystems launches the world’s first GMP-grade DLL-4 Protein

ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions.

Investors-in-residence join Cancer Research Horizons to advance Ventures team

Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence.

Milner, AstraZeneca, and MRC partner for functional genomics advancements

The University of Cambridge announced a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute.

RoslinCT to manufacture world’s-first CRISPR-based therapy

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Rosalind Franklin Institute appoints Professor Paul Matthews as new director

The Rosalind Franklin Institute announces Professor Paul Matthews as its new Institute Director. Professor Matthews is a world class clinician scientist with over 30 years of experience working on neurodegenerative disorders.

Brainomix expands to the US with FDA-cleared Stroke AI Platform

Brainomix, the AI-powered medtech solutions company, has heralded its continued US expansion with the launch of its full suite of FDA-cleared modules in its Brainomix 360 platform for stroke care.

Cancer Research Horizons opens nominations for its Innovation & Entrepreneurship Awards 2024

Cancer Research Horizons, the innovation arm of Cancer Research UK, has opened nominations for its Innovation & Entrepreneurship Awards 2024, which celebrate the UK’s most enterprising efforts in oncology.

Merit reaches key project milestone for Moderna's clinical laboratories

Northumberland-headquartered Merit, the UK’s leading industrialised construction and digital manufacturing specialist, has reached a significant project milestone for Moderna’s clinical laboratories project.

PrecisionLife announces new appointments to launch diagnostics and healthcare strategy

PrecisionLife® announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.


More within